Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer.

Korangath P, Barnett JD, Sharma A, Henderson ET, Stewart J, Yu SH, Kandala SK, Yang CT, Caserto JS, Hedayati M, Armstrong TD, Jaffee E, Gruettner C, Zhou XC, Fu W, Hu C, Sukumar S, Simons BW, Ivkov R.

Sci Adv. 2020 Mar 25;6(13):eaay1601. doi: 10.1126/sciadv.aay1601. eCollection 2020 Mar.

PMID:
32232146
2.

Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors.

Wang H, Sové RJ, Jafarnejad M, Rahmeh S, Jaffee EM, Stearns V, Roussos Torres ET, Connolly RM, Popel AS.

Front Bioeng Biotechnol. 2020 Feb 25;8:141. doi: 10.3389/fbioe.2020.00141. eCollection 2020.

3.

Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.

Christenson ES, Jaffee E, Azad NS.

Lancet Oncol. 2020 Mar;21(3):e135-e145. doi: 10.1016/S1470-2045(19)30795-8. Review.

PMID:
32135117
4.

SINGLE-CELL IMMUNE COMPETENCY SIGNATURES ASSOCIATE WITH SURVIVAL IN PHASE 2 GVAX AND CRS-207 RANDOMIZED STUDIES IN METASTATIC PANCREATIC CANCER PATIENTS.

Nair N, Chen SY, Lemmens E, Chang S, Le DT, Jaffee EM, Murphy A, Whiting C, Müller T, Brockstedt DG.

Cancer Immunol Res. 2020 Mar 4. pii: canimm.0650.2019. doi: 10.1158/2326-6066.CIR-19-0650. [Epub ahead of print]

PMID:
32132105
5.

NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma.

Suresh R, Barakat DJ, Barberi T, Zheng L, Jaffee E, Pienta KJ, Friedman AD.

J Immunother Cancer. 2020 Jan;8(1). pii: e000244. doi: 10.1136/jitc-2019-000244.

6.

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.

Yarchoan M, Huang CY, Zhu Q, Ferguson AK, Durham JN, Anders RA, Thompson ED, Rozich NS, Thomas DL 2nd, Nauroth JM, Rodriguez C, Osipov A, De Jesus-Acosta A, Le DT, Murphy AG, Laheru D, Donehower RC, Jaffee EM, Zheng L, Azad NS.

Cancer Med. 2020 Feb;9(4):1485-1494. doi: 10.1002/cam4.2763. Epub 2019 Dec 26.

7.

Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes.

Ho WJ, Yarchoan M, Charmsaz S, Munday RM, Danilova L, Sztein MB, Fertig EJ, Jaffee EM.

JCI Insight. 2020 Jan 30;5(2). pii: 132286. doi: 10.1172/jci.insight.132286.

8.

Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors.

Ho WJ, Jaffee EM.

J Clin Invest. 2020 Jan 2;130(1):71-73. doi: 10.1172/JCI133685.

9.

Correction: Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson L, Karasic T, Llovet J, Finn R, Groopman J, El-Serag H, Monga S, Wang XW, Karin M, Schwartz R, Tanabe K, Roberts L, Gunaratne P, Tsung A, Brown K, Lawrence T, Salem R, Singal A, Kim A, Rabiee A, Resar L, Meyer J, Hoshida Y, He AR, Ghoshal K, Ryan P, Jaffee E, Guha C, Mishra L, Coleman N, Ahmed M.

Cancer Res. 2019 Nov 15;79(22):5897. doi: 10.1158/0008-5472.CAN-19-2958. No abstract available.

10.

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade.

Stein JE, Lipson EJ, Cottrell TR, Forde PM, Anders RA, Cimino-Mathews A, Thompson ED, Allaf ME, Yarchoan M, Feliciano J, Wang H, Jaffee EM, Pardoll DM, Topalian SL, Taube JM.

Clin Cancer Res. 2020 Feb 1;26(3):545-551. doi: 10.1158/1078-0432.CCR-19-2379. Epub 2019 Oct 31.

PMID:
31672770
11.

MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.

Yarchoan M, Mohan AA, Dennison L, Vithayathil T, Ruggieri A, Lesinski GB, Armstrong TD, Azad NS, Jaffee EM.

PLoS One. 2019 Oct 31;14(10):e0224600. doi: 10.1371/journal.pone.0224600. eCollection 2019.

12.

Equity and diversity in academic medicine: a perspective from the JCI editors.

Resar LM, Jaffee EM, Armanios M, Jackson S, Azad NS, Horton MR, Kaplan MJ, Laiho M, Maus MV, Sumner CJ, Wheelan SJ, Wills-Karp M.

J Clin Invest. 2019 Oct 1;129(10):3974-3977. doi: 10.1172/JCI130902. No abstract available.

13.

Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM.

Cancer Res. 2019 Sep 1;79(17):4326-4330. doi: 10.1158/0008-5472.CAN-19-0803. Erratum in: Cancer Res. 2019 Nov 15;79(22):5897.

14.

Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.

Llosa NJ, Luber B, Siegel N, Awan AH, Oke T, Zhu Q, Bartlett BR, Aulakh LK, Thompson ED, Jaffee EM, Durham JN, Sears CL, Le DT, Diaz LA Jr, Pardoll DM, Wang H, Housseau F, Anders RA.

Cancer Immunol Res. 2019 Oct;7(10):1574-1579. doi: 10.1158/2326-6066.CIR-18-0927. Epub 2019 Aug 22.

15.

Targeting Mechanoresponsive Proteins in Pancreatic Cancer: 4-Hydroxyacetophenone Blocks Dissemination and Invasion by Activating MYH14.

Surcel A, Schiffhauer ES, Thomas DG, Zhu Q, DiNapoli KT, Herbig M, Otto O, West-Foyle H, Jacobi A, Kräter M, Plak K, Guck J, Jaffee EM, Iglesias PA, Anders RA, Robinson DN.

Cancer Res. 2019 Sep 15;79(18):4665-4678. doi: 10.1158/0008-5472.CAN-18-3131. Epub 2019 Jul 29.

16.

Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data.

Davis-Marcisak EF, Sherman TD, Orugunta P, Stein-O'Brien GL, Puram SV, Roussos Torres ET, Hopkins AC, Jaffee EM, Favorov AV, Afsari B, Goff LA, Fertig EJ.

Cancer Res. 2019 Oct 1;79(19):5102-5112. doi: 10.1158/0008-5472.CAN-18-3882. Epub 2019 Jul 23.

17.

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.

Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG.

Clin Cancer Res. 2019 Oct 1;25(19):5787-5798. doi: 10.1158/1078-0432.CCR-19-0070. Epub 2019 Jul 1.

PMID:
31263030
18.

Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts.

Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA.

Cancer Discov. 2019 Aug;9(8):1102-1123. doi: 10.1158/2159-8290.CD-19-0094. Epub 2019 Jun 13.

19.

Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.

Blair AB, Kim VM, Muth ST, Saung MT, Lokker N, Blouw B, Armstrong TD, Jaffee EM, Tsujikawa T, Coussens LM, He J, Burkhart RA, Wolfgang CL, Zheng L.

Clin Cancer Res. 2019 Sep 1;25(17):5351-5363. doi: 10.1158/1078-0432.CCR-18-4192. Epub 2019 Jun 11.

20.

Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice.

Jurcak NR, Rucki AA, Muth S, Thompson E, Sharma R, Ding D, Zhu Q, Eshleman JR, Anders RA, Jaffee EM, Fujiwara K, Zheng L.

Gastroenterology. 2019 Sep;157(3):838-850.e6. doi: 10.1053/j.gastro.2019.05.065. Epub 2019 Jun 1.

PMID:
31163177
21.

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).

Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM.

Clin Cancer Res. 2019 Sep 15;25(18):5493-5502. doi: 10.1158/1078-0432.CCR-18-2992. Epub 2019 May 24.

PMID:
31126960
22.

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.

Kim VM, Blair AB, Lauer P, Foley K, Che X, Soares K, Xia T, Muth ST, Kleponis J, Armstrong TD, Wolfgang CL, Jaffee EM, Brockstedt D, Zheng L.

J Immunother Cancer. 2019 May 22;7(1):132. doi: 10.1186/s40425-019-0601-5.

23.

Current Status of Immunotherapies for Treating Pancreatic Cancer.

Wu AA, Jaffee E, Lee V.

Curr Oncol Rep. 2019 May 17;21(7):60. doi: 10.1007/s11912-019-0811-5. Review.

PMID:
31101991
24.

Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.

Danilova L, Ho WJ, Zhu Q, Vithayathil T, De Jesus-Acosta A, Azad NS, Laheru DA, Fertig EJ, Anders R, Jaffee EM, Yarchoan M.

Cancer Immunol Res. 2019 Jun;7(6):886-895. doi: 10.1158/2326-6066.CIR-18-0822. Epub 2019 May 1.

PMID:
31043417
25.

Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4+ effector T cell infiltration into murine pancreatic tumors.

Zaidi N, Quezada SA, Kuroiwa JMY, Zhang L, Jaffee EM, Steinman RM, Wang B.

Ann N Y Acad Sci. 2019 Jun;1445(1):62-73. doi: 10.1111/nyas.14049. Epub 2019 Apr 4.

PMID:
30945313
26.

Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.

Kim AK, Gani F, Layman AJ, Besharati S, Zhu Q, Succaria F, Engle EL, Bhaijee F, Goggins MB, Llosa NJ, Pawlik TM, Yarchoan M, Jaffee EM, Simons HC, Taube JM, Anders RA.

Cancer Immunol Res. 2019 May;7(5):805-812. doi: 10.1158/2326-6066.CIR-18-0499. Epub 2019 Mar 22.

PMID:
30902819
27.

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, Jaffee EM.

JCI Insight. 2019 Mar 21;4(6). pii: 126908. doi: 10.1172/jci.insight.126908. eCollection 2019 Mar 21.

28.

Empowering Clinician-Educators with Chalk Talk Teaching Scripts.

Cawkwell PB, Jaffee EG, Frederick D, Gerken AT, Vestal HS, Stoklosa J.

Acad Psychiatry. 2019 Aug;43(4):447-450. doi: 10.1007/s40596-019-01042-w. Epub 2019 Feb 21. No abstract available.

PMID:
30793256
29.

Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-Cells.

Jin J, Krishnamachary B, Barnett JD, Chatterjee S, Chang D, Mironchik Y, Wildes F, Jaffee EM, Nimmagadda S, Bhujwalla ZM.

ACS Appl Mater Interfaces. 2019 Feb 27;11(8):7850-7861. doi: 10.1021/acsami.8b22309. Epub 2019 Feb 14.

30.

A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.

Ma HS, Poudel B, Torres ER, Sidhom JW, Robinson TM, Christmas B, Scott B, Cruz K, Woolman S, Wall VZ, Armstrong T, Jaffee EM.

Cancer Immunol Res. 2019 Mar;7(3):428-442. doi: 10.1158/2326-6066.CIR-18-0061. Epub 2019 Jan 14.

31.

Immune cells track hard-to-target brain tumours.

Zaidi N, Jaffee EM.

Nature. 2019 Jan;565(7738):170-171. doi: 10.1038/d41586-018-07728-9. No abstract available.

32.

Transcriptional profiling identifies novel regulators of macrophage polarization.

Gerrick KY, Gerrick ER, Gupta A, Wheelan SJ, Yegnasubramanian S, Jaffee EM.

PLoS One. 2018 Dec 7;13(12):e0208602. doi: 10.1371/journal.pone.0208602. eCollection 2018.

33.

Immunotherapy transforms cancer treatment.

Zaidi N, Jaffee EM.

J Clin Invest. 2019 Jan 2;129(1):46-47. doi: 10.1172/JCI126046. Epub 2018 Dec 3. No abstract available.

34.

Peptide-based PET quantifies target engagement of PD-L1 therapeutics.

Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S.

J Clin Invest. 2019 Feb 1;129(2):616-630. doi: 10.1172/JCI122216. Epub 2019 Jan 7.

35.

Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.

Saung MT, Muth S, Ding D, Thomas DL 2nd, Blair AB, Tsujikawa T, Coussens L, Jaffee EM, Zheng L.

J Immunother Cancer. 2018 Nov 13;6(1):118. doi: 10.1186/s40425-018-0435-6.

36.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S.

Ann Oncol. 2019 Jan 1;30(1):44-56. doi: 10.1093/annonc/mdy495. Review.

37.

Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.

Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, Woolman S, Armstrong TD, Connolly RM, Azad NA, Jaffee EM, Roussos Torres ET.

Cancer Immunol Res. 2018 Dec;6(12):1561-1577. doi: 10.1158/2326-6066.CIR-18-0070. Epub 2018 Oct 19.

38.

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.

Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, Woolman S, Vithayathil T, Glickman LH, Ndubaku CO, McWhirter SM, Dubensky TW Jr, Armstrong TD, Jaffee EM, Zaidi N.

JCI Insight. 2018 Oct 18;3(20). pii: 122857. doi: 10.1172/jci.insight.122857.

39.

Emerging strategies for combination checkpoint modulators in cancer immunotherapy.

Popovic A, Jaffee EM, Zaidi N.

J Clin Invest. 2018 Aug 1;128(8):3209-3218. doi: 10.1172/JCI120775. Epub 2018 Aug 1. Review.

40.

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM.

JCI Insight. 2018 Jul 12;3(13). pii: 122092. doi: 10.1172/jci.insight.122092.

41.

Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.

Adler BL, Pezhouh MK, Kim A, Luan L, Zhu Q, Gani F, Yarchoan M, Chen J, Voltaggio L, Parian A, Lazarev M, Lauwers GY, Pawlik TM, Montgomery EA, Jaffee E, Le DT, Taube JM, Anders RA.

J Intern Med. 2018 Jun;283(6):568-577. doi: 10.1111/joim.12744. Epub 2018 Mar 24.

42.

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.

Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA.

Oncotarget. 2017 Dec 14;8(69):114268-114280. doi: 10.18632/oncotarget.23217. eCollection 2017 Dec 26.

43.

Pancreatic cancer: Next-generation algorithms for neoantigen selection.

Hopkins A, Jaffee E.

Nat Rev Gastroenterol Hepatol. 2018 Mar;15(3):135-136. doi: 10.1038/nrgastro.2017.184. Epub 2018 Jan 10. No abstract available.

44.

Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer.

Murphy AG, Foley K, Rucki AA, Xia T, Jaffee EM, Huang CY, Zheng L.

Oncotarget. 2017 Nov 15;8(63):106405-106414. doi: 10.18632/oncotarget.22433. eCollection 2017 Dec 5.

45.

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Yarchoan M, Hopkins A, Jaffee EM.

N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444. No abstract available.

46.

Health Literacy and Hospital Length of Stay: An Inpatient Cohort Study.

Jaffee EG, Arora VM, Matthiesen MI, Meltzer DO, Press VG.

J Hosp Med. 2017 Dec;12(12):969-973. doi: 10.12788/jhm.2848. Epub 2017 Sep 20.

PMID:
29236095
47.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

48.

Report on the Third FDA-AACR Oncology Dose-Finding Workshop.

Emens LA, Bruno R, Rubin EH, Jaffee EM, McKee AE.

Cancer Immunol Res. 2017 Dec;5(12):1058-1061. doi: 10.1158/2326-6066.CIR-17-0590.

49.

Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Rao AD, Liu Y, von Eyben R, Hsu CC, Hu C, Rosati LM, Parekh A, Ng K, Hacker-Prietz A, Zheng L, Pawlik TM, Laheru DA, Jaffee EM, Weiss MJ, Le DT, Hruban RH, De Jesus-Acosta A, Wolfgang CL, Narang AK, Chang DT, Koong AC, Herman JM.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):486-489. doi: 10.1016/j.ijrobp.2017.10.001. Epub 2017 Oct 12.

PMID:
29157747
50.

Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective.

Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR, Jackson JF, Le DT, Jaffee EM, Zheng L, Laheru DA, He J, Pawlik TM, Weiss MJ, Wolfgang CL, Herman JM.

Ann Surg Oncol. 2018 Jan;25(1):280-289. doi: 10.1245/s10434-017-6134-6. Epub 2017 Oct 23.

PMID:
29063299

Supplemental Content

Loading ...
Support Center